Home 2017-05-08T02:45:42+00:00

Novel cancer therapies targeting key cancer pathways

READ MORE
Prescient Therapeutics PTX

We are a clinical stage oncology company developing novel drugs
that show great promise as potential new therapies to treat a range of cancers.

prescient therapeutics

OUR COMPANY

Prescient Therapeutics’ novel compounds inhibit key tumor survival pathways, inhibiting cancer growth and overcoming resistance to prior therapies.

Read more

prescient therapeutics

OUR SCIENCE

Our technologies emanate from renowned institutions Yale University and the Moffitt Cancer Center and are backed by a myriad of peer review publications.

Read more

prescient therapeutics

LATEST NEWS

22/06/2017Gold Coast Investor Conference PresentationPDF
19/06/2017Novel PTX-100 Cancer Approach Published in NaturePDF
29/05/2017 Clinical Trial UpdatePDF
16/05/2017PTX Broker PresentationPDF
12/05/2017European Patent Granted for PTX-200PDF